Form 4: ARS Pharmaceuticals Director Pratik Shah Reports Gift of Shares
SEC Form 4 Filing
Director Pratik Shah reports gifting shares of ARS Pharmaceuticals stock, both directly and indirectly through his spouse, in transactions dated June 13, 2024.
Summary
- On June 13, 2024, Pratik Shah, a director of ARS Pharmaceuticals, reported a transaction involving the gift of 200,000 shares of common stock.
- These shares were gifted by Mr. Shah's spouse to his father-in-law.
- Additionally, Mr. Shah's spouse gifted 1,132,900 shares to an irrevocable trust where she is the settlor.
- Following these transactions, Mr. Shah directly owns 0 shares and indirectly owns 1,132,900 shares through his spouse and 4,824,554 shares through The Pratik Shah Living Trust dated June 15, 2011, of which he is the trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports a gift of shares, which doesn't inherently indicate positive or negative prospects for the company.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily reflect a strategic shift for ARS Pharmaceuticals.
Related Party Transactions
- The transactions involve gifts to related parties: Mr. Shah's father-in-law and an irrevocable trust where his spouse is the settlor.
Stakeholder Impact
- The impact on stakeholders is likely minimal, as these are personal transactions and do not directly affect the company's operations or financial standing.
Key Dates
| Date | Description |
|---|---|
| June 15, 2011 | Date of The Pratik Shah Living Trust |
| 06/13/2024 | Date of the share gifting transactions |
| 06/17/2024 | Date of the report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.